Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma.
Jason R WestinFrederick L LockeMichael J DickinsonArmin GhobadiMahmoud ElsawyTom van MeertenDavid Bernard MiklosMatthew L UlricksonMiguel-Ángel PeralesUmar FarooqLuciano WannessonLori A LeslieMarie José KerstenCaron A JacobsonJohn M PagelGerald Georg WulfPatrick B JohnstonAaron P RapoportLinqiu DuSaran VardhanabhutiSimone FilostoJina ShahJulia Thornton SniderPaul ChengChristina ToOlalekan O OluwoleAnna SuredaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Axi-cel is an effective second-line curative-intent therapy with a manageable safety profile and improved PROs for patients ≥65 years with R/R LBCL.
Keyphrases